Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting

CAMBRIDGE, Mass - 08.12.2016

Biogen (NASDAQ: BIIB) announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimer’s disease (AD), today at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.

News overview

This website uses cookies, with the aim of ensuring that you have the best possible online experience. In using our website, you are giving your consent to the terms and conditions of our Privacy policy

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue